Sanofi

Genzyme Corporation

Ronnie Rong Wei

Gary J Nabel

Huawei Qiu

Ercole Rao

Christian Beil

Catherine Prades

Zhi-Yong Yang

Lan Wu

Edward Seung

Seng H Cheng

Christian Lange

Yunxiang Zhu

Cendrine Lemoine

Clark Qun Pan

William Harold Brondyk

Béatrice Cameron

Tarik Dabdoubi

Ling Xu

Jochen Beninga

Sunghae Park

Yangde Chen

Carsten Corvey

Timothy D Connors

Canwen Jiang

Wulf Dirk Leuschner

Hongmei Zhao

Magali Mathieu

Catherine Devaud

Jozsef Karman

Dietmar Hoffmann

Maureen Magnay

Aaron Moulin

Tristan Magnay

Leila Sevigny

Joerg Thomas Regula

Chih-Jen Wei

Kurt Swanson

Joerg Birkenfeld

Zhen Xing

Rebecca Sendak

Yves Sabbagh

Yu Qiu

Yanfeng Zhou

HyunSuk Cho

Heather Kamp

This disclosure relates to antigenic OspA polypeptides and their use in eliciting antibodies against OspA. Also disclosed are antigenic polypeptides comprising an OspA polypeptide and a ferritin protein.

Antigenic OspA polypeptides

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific binding proteins, methods, and uses thereof

The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.

Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection

Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

FGFR3 antibodies and methods of use

Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Multispecific binding molecules having specificity to dystroglycan and laminin-2

The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific and/or trivalent binding proteins

The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.

Anti-CD38 antibodies and methods of use

The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.

Inhibitors of T-cell activation

Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-&#x3b2; (TGF&#x3b2;). TGF&#x3b2;-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGF&#x3b2;1, compared to human TGF&#x3b2;2 and human TGF&#x3b2;3, or may selectively bind human TGF&#x3b2;3, compared to human TGF&#x3b2;1 and human TGF&#x3b2;2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGF&#x3b2;2 and by another co-crystal structure of the scFv version of GC1008 bound to TGF&#x3b2;1.

Engineered anti-TGF-&#x3b2; antibodies and antigen-binding fragments

Engineered anti-TGF-beta antibodies and antigen-binding fragments

Anti-human CD52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments. The antibodies and fragments can be used in therapeutic applications to treat, for example, autoimmune diseases, cancer, and graft rejection.

Anti-CD52 antibodies

Growing community of inventors

Cambridge, MA, United States of America

Ronnie Rong Wei